4971 results for "Psychedelics"
Repeated low doses of psilocybin reduces perceived symptom severity of obsessive-compulsive disorder, but fails to restore cognitive flexibility: A case study of identical twins
OpenAlex – December 30, 2024
Summary
Low-dose psilocybin shows promise for Obsessive compulsive disorder symptoms, even without psychedelic effects. A case involving identical twins (N=2) revealed the affected twin experienced a notable reduction in OCD symptomatology and improved emotional well-being after self-administering psilocybin. However, despite these improvements in behavior, deficits in cognitive flexibility persisted compared to the unaffected twin. This suggests that while psilocybin may alleviate certain aspects of clinical psychology, it might not fully address underlying cognition impairments. This area of Psychedelics and Drug Studies warrants further investigation.
Abstract
Background: Obsessive-Compulsive Disorder (OCD) presents significant challenges to individuals mental health, characterized by intrusive thoughts a...
Magic mushrooms and mood: exploring Psilocybin as a depression treatment
Journal of the Pakistan Medical Association – December 20, 2025
Summary
A significant development in Psychiatry: Psilocybin, a potent hallucinogen, is emerging as a viable treatment for Major Depressive Disorder. This psychedelic compound acts on serotonergic receptors, inducing altered perception and psychological effects. Recognized by the FDA with "breakthrough" therapy status, Psilocybin offers a novel approach in Medicine. Studies highlight its effectiveness in alleviating depressive symptoms, often integrated with psychological therapy. Its potential to transform mental health treatment is driving intense interest in Psychedelics and Drug Studies.
Abstract
Dear Editor, In view of ongoing global research on mental health, especially Major Depressive Disorder, we would like to draw attention to a psyche...
Age- and estrous-dependent effects of psilocybin in rats
OpenAlex – January 14, 2025
Summary
Psilocybin, a potent hallucinogen, elicits vastly different responses depending on age and biological sex. Adolescent rats (P35/P45) given 1 mg/kg psilocybin showed no head twitch responses, unlike robust reactions in adults. Furthermore, adult females in diestrus exhibited increased responses to the psychedelic compared to those in proestrus, highlighting the estrous cycle's impact. These findings are crucial for psychology, internal medicine, and future psychedelics and drug studies, emphasizing neuroendocrine regulation and neurotransmitter receptor influence on behavior within neuroscience.
Abstract
Abstract Psilocybin, a psychedelic compound in “magic” mushrooms, has promise as a novel treatment for psychiatric disorders, many of which are mor...
A history of the European Medical Society for Psycholytic Therapy (EPT) 1964–1974
Drug Science Policy and Law – January 01, 2024
Summary
A forgotten chapter in **Psychology** reveals that the original "psychedelic **Renaissance**" involved a unique approach to **Medicine**. The European Medical Society for Psycholytic Therapy, founded in **1965**, coordinated **Psychotherapists** using low-dose **Psilocybin** and similar drugs in serial sessions alongside long-term therapy. This method, termed psycholytic therapy, contrasts sharply with today's high-dose, short-term models in **Psychedelics and Drug Studies**. Unearthing its history from archives offers crucial insights for modern **Complementary and Alternative Medicine Studies**, informing future standards for **Psilocybin** and other substances from **chemical synthesis and alkaloids**.
Abstract
The emergence of a so-called psychedelic renaissance has been proposed to characterize the revival of research into (psycho-)therapies using psyche...
#35647 Alternative pharmacological approaches to chronic pain management
OpenAlex – September 01, 2023
Summary
Emerging pharmacological approaches offer new hope for chronic pain management, potentially reducing reliance on addictive analgesics in medicine. Promise emerges from cannabis, psychedelics, and dissociative hypnotics like ketamine. While cannabis is most explored, its adverse effects need understanding. Ketamine shows potential but raises abuse concerns, critical for pharmacology and intensive care medicine. Psychedelics, though least understood, demonstrate promise in preliminary small studies, requiring more study on dose-dependent adverse effects. Significant progress is crucial before these options become standard, yet they could improve patients' quality of life.
Abstract
Please confirm that an ethics committee approval has been applied for or granted: Not relevant (see information at the bottom of this page) Backgro...
Therapeutic frameworks in integration sessions in substance‐assisted psychotherapy: A systematised review
Clinical Psychology & Psychotherapy – December 26, 2023
Summary
Despite growing interest in Psychedelics and Drug Studies, no specific psychotherapeutic approach for integrating psychedelic experiences into daily life has demonstrated efficacy. A comprehensive review of 75 diverse publications, spanning clinical trials to opinion papers, found that while integration is crucial for safe substance-assisted psychotherapy, no single therapeutic framework is empirically supported. Most current Psychology applications, often drawing from humanistic traditions, lack rigorous evidence for a Psychotherapist. This critical gap, impacting Neurotransmitter Receptor Influence on Behavior, is evident across databases like PsycINFO and MEDLINE.
Abstract
Abstract Serotonergic psychedelics and related substances have been explored as potential adjuncts in substance‐assisted psychotherapy (SAPT) for t...
From Ego to Death: Validation of the Ego-Dissolution Scale (EDS)
OpenAlex – July 27, 2022
Summary
Psychedelics like Ayahuasca and Psilocybin profoundly alter the self, offering deep insights and pleasure, challenging psychology's view of the ego. An online survey of 207 participants revealed six distinct facets of ego-dissolution, touching on identity relevant to social psychology. Ayahuasca and DMT induced stronger psychic experiences than LSD and psilocybin, offering new life perspectives. This work, part of Psychedelics and Drug Studies encompassing areas like Cannabis and Cannabinoid Research, contributes to understanding the Id, ego, and super-ego.
Abstract
<p>Disruptions to the sense of self are dotted across cultures and times in rituals involving hallucinogens, sensory deprivation, trance poss...
Lysergic acid diethylamide induces increased signalling entropy in rats’ prefrontal cortex
Journal of Neurochemistry – November 03, 2021
Summary
Psychedelics like Lysergic acid diethylamide show remarkable promise for treating psychiatric conditions. Neuroscience reveals this chemical, an alkaloid, profoundly reorganizes gene networks within the prefrontal cortex of rats. Signalling pathways become more complex and less centralized, increasing brain plasticity. This chemical synthesis-derived compound influences neurotransmitter receptors, mirroring increased brain entropy seen in human psychology studies. Understanding these molecular changes offers crucial insights into how psychedelics could benefit mental health.
Abstract
Abstract Psychedelic drugs are gaining attention from the scientific community as potential new compounds for the treatment of psychiatric diseases...
Serotonin 2A Receptor Signaling Underlies LSD-induced Alteration of the Neural Response to Dynamic Changes in Music
Cerebral Cortex – September 12, 2017
Summary
Psychedelics profoundly alter music perception. Neuroscience reveals that the 5-HT2A receptor, a key Serotonin receptor, critically influences how our brains process music's tonal structure. Using biochemical analysis and sensing techniques, 25 healthy adults showed altered neural responses to music after LSD, which were blocked by Ketanserin (a 5-HT2A antagonist). This work in Cognitive Psychology and Psychedelics and Drug Studies highlights the 5-HT2A receptor's role in the emotional depth and meaningfulness of music, informing Neuroscience and Music Perception.
Abstract
Abstract Classic psychedelic drugs (serotonin 2A, or 5HT2A, receptor agonists) have notable effects on music listening. In the current report, bloo...
The Hallucinogenic Serotonin2A Receptor Agonist, 2,5-Dimethoxy-4-Iodoamphetamine, Promotes cAMP Response Element Binding Protein-Dependent Gene Expression of Specific Plasticity-Associated Genes in the Rodent Neocortex
Frontiers in Molecular Neuroscience – December 24, 2021
Summary
Psychedelics rapidly enhance brain plasticity. A synthetic psychedelic, DOI, acting on the 5-HT 2A receptor, quickly upregulates genes vital for synaptic plasticity in rat neocortex. Cell biology experiments using rat cortical neurons and CREB-deficient mice reveal the transcription factor CREB is crucial. This neuroscience shows DOI stimulates CREB, increasing expression of immediate early genes like *Arc*. This upregulation was blocked without the 5-HT 2A receptor or CREB, explaining these drug studies' profound effects.
Abstract
Psychedelic compounds that target the 5-HT 2A receptor are reported to evoke psychoplastogenic effects, including enhanced dendritic arborization a...
AVANÇOS NO TRATAMENTO DE TRANSTORNOS MENTAIS: Uma análise bibliométrica global da pesquisa sobre psicodélicos clássicos
Psicologia e Saúde em Debate – October 18, 2024
Summary
Research into classic psychedelics for mental health treatment is experiencing a dramatic global surge. An analysis of 4,235 publications from 91 countries reveals a strong, accelerating trend in Psychedelics and Drug Studies. Publications on LSD and psilocybin, central to Psychology and Mental Health, show particularly robust growth, with yearly increases correlating strongly at 0.92 and 0.94 respectively. This expanding evidence base offers new avenues for psychotherapists seeking innovative therapeutic options.
Abstract
Classic psychedelics are being globally investigated for their therapeutic potential in mental disorders, however, the literature offers little inf...
Psilocin, LSD, mescaline, and DOB all induce broadband desynchronization of EEG and disconnection in rats with robust translational validity
Translational Psychiatry – October 02, 2021
Summary
Psychedelics like mescaline, LSD, and psilocin significantly alter brain activity, as demonstrated in a study involving 20 freely moving rats. These substances led to a global decrease in EEG activity across 1–40 Hz, particularly affecting the frontal and sensorimotor cortex. Connectivity analyses revealed reduced global connectivity, echoing findings from human studies. Interestingly, a rebound in occipital theta activity was observed after mescaline and LSD treatment. The results suggest strong translational validity for understanding the effects of serotonergic psychedelics on brain function.
Abstract
Abstract Serotonergic psychedelics are recently gaining a lot of attention as a potential treatment of several neuropsychiatric disorders. Broadban...
Enhancement of Creative Expression and Entoptic Phenomena as After-Effects of Repeated Ayahuasca Ceremonies
Journal of Psychoactive Drugs – July 01, 2012
Summary
Engaging in ayahuasca ceremonies can significantly enhance creativity, as evidenced by a study involving 40 participants who completed the Torrance Tests of Creative Thinking before and two days after a two-week ritual series. Results showed a marked increase in highly original solutions post-ceremony. Additionally, participants exhibited higher phosphenic responses, suggesting enhanced sensory activity linked to creativity. In contrast, 21 comparison subjects, with fewer recent psychedelic experiences, demonstrated lower baseline creativity levels. This highlights the potential of psychedelics in fostering creative expression through ritualistic practices.
Abstract
Studying the effect of psychedelic substances on expression of creativity is a challenging problem. Our primary objective was to study the psychome...
A Phase 1, Dose-Ranging Study to Assess Safety and Psychoactive Effects of a Vaporized 5-Methoxy-N,N-Dimethyltryptamine Formulation (GH001) in Healthy Volunteers
European Psychiatry – June 01, 2022
Summary
A novel vaporized formulation of 5-MeO-DMT, tested on 22 healthy volunteers, demonstrated dose-related increases in psychedelic experiences without significant adverse effects. Participants reported heightened intensity on various scales, particularly after doses of 6, 12, and 18 mg. While cognitive functioning, mood, and well-being remained stable, individualized dose escalation led to the strongest psychoactive responses. Notably, vital signs were unaffected, and mild adverse effects like nausea resolved quickly. This approach may enhance therapeutic outcomes in treating depression with psychedelics.
Abstract
Introduction 5-Methoxy-N,N-Dimethyltryptamine (5-MeO-DMT) is a tryptamine with ultra-rapid onset and short duration of psychedelic effects. Prospec...
Ayahuasca – a review of historical, pharmacological, and therapeutic aspects
OpenAlex – February 21, 2023
Summary
Ayahuasca, a potent psychedelic brew from the Amazon rainforest, has garnered significant global interest, with a notable rise in tourism for its consumption. Anecdotal reports highlight diverse experiences, with some individuals reporting enhanced mental health and personality changes. A review of 30 studies indicates that approximately 70% of participants experienced positive psychological outcomes after using ayahuasca. As retreat centers proliferate worldwide, understanding its neurochemical mechanisms and therapeutic potential becomes crucial for both psychotherapists and those interested in psychedelics as medicine.
Abstract
Ayahuasca is a psychedelic plant brew originating from the Amazon Rainforest. It is formed from two basic components, the Banisteriopsis caapi vine...
Ayahuasca Tourism: Curating Authenticity in Transformative Times (Field Note)
Nova Religio The Journal of Alternative and Emergent Religions – August 01, 2024
Summary
Ayahuasca is rapidly gaining popularity, with a growing number of churches and retreat centers emerging globally. Many individuals travel to the Amazon, seeking an authentic shamanic experience, contributing to a diverse ayahuasca ecosystem. This phenomenon reflects a broader trend in psychedelic tourism, where motivations range from recreational use to spiritual exploration. With increasing interest, the dynamics of this ecosystem are shifting, influenced by both historical practices and contemporary tourist interactions, highlighting the intersection of sociology, geography, and transformative learning in the context of psychedelics.
Abstract
ABSTRACT: Motivated by multiple factors collectively related to what is often termed the Psychedelic Renaissance, people increasingly consume psych...
DataSheet1_A Phase 1, Dose-Ranging Study to Assess Safety and Psychoactive Effects of a Vaporized 5-Methoxy-N, N-Dimethyltryptamine Formulation (GH001) in Healthy Volunteers.docx
Figshare – November 25, 2021
Summary
Higher doses of 5-MeO-DMT, a tryptamine, significantly enhanced the intensity of psychedelic experiences in healthy volunteers, with notable effects observed at 6 mg (N=6), 12 mg (N=4), and 18 mg (N=4) compared to the lowest 2 mg dose (N=4). Evaluations using various questionnaires indicated that individualized dose escalation (N=4) maximized these experiences. Importantly, mood, cognition, and well-being remained unaffected, and adverse effects were mild, such as nausea. Vital signs showed no significant changes, suggesting good tolerability for this novel psychedelic formulation.
Abstract
<p>5-Methoxy-N,N-Dimethyltryptamine (5-MeO-DMT) is a tryptamine with ultra-rapid onset and short duration of psychedelic effects. Prospective...
Dark Classics in Chemical Neuroscience: Mescaline
ACS Chemical Neuroscience – May 30, 2018
Summary
Mescaline, a psychedelic compound found in cacti like peyote and wachuma, has been used for over 6,000 years across the Americas. Despite historical prohibition due to misconceptions, its popularity has surged in recent decades. Mescaline’s effects primarily stem from its action as a 5-HT2A serotonin receptor agonist, while also interacting with 5-HT1A and α2A receptors. Its low potency has limited recreational use, yet growing interest in psychedelics may uncover therapeutic benefits and deepen understanding of hallucinogen pharmacology.
Abstract
Archeological studies in the United States, Mexico, and Peru suggest that mescaline, as a cactus constituent, has been used for more than 6000 year...
Isotopic DMT as a Probe of Spinorial Consciousness
Zenodo (CERN European Organization for Nuclear Research) – March 11, 2026
Summary
A groundbreaking protocol aims to test the hypothesis that psychedelics like DMT influence consciousness through a radical pair mechanism at the serotonin 5-HT2A receptor. By creating isotopically labeled variants (13C-DMT and 15N-DMT), the study modifies nuclear spins while preserving key molecular properties. With a sample size of 100 mice, deuterium substitution shows a significant Kinetic Isotope Effect (∆m = +100%), while 13C and 15N substitutions yield negligible effects (∆m = +8% and +7%, respectively). Observed changes in psychedelic experiences could provide direct evidence for this mechanism.
Abstract
We propose a decisive experimental protocol to test the hypothesis that the psychedelic state involves the radical pair mechanism (RPM) operating a...
LSD Relaxes Structural Constraints on Brain Dynamics and Default Mode Decoupling Tracks Ego Dissolution
OpenAlex – March 05, 2026
Summary
Psychedelics like LSD significantly alter brain function, revealing a remarkable decoupling of low-frequency brain activity from structural constraints. In a study involving 30 participants, LSD led to a 40% increase in flexibility within the default mode network, which is associated with ego dissolution. While low-frequency activity showed widespread reorganization, high-frequency gamma activity underwent selective adjustments. This suggests that psychedelics promote a unique rebalancing of neural dynamics, potentially enhancing therapeutic effects by loosening rigid structural limitations and improving communication among brain networks involved in self-awareness and perception.
Abstract
Abstract Psychedelics profoundly alter conscious experience, yet how they reshape the relationship between brain anatomy and function remains uncle...
Regulatory Alignment of Psilocybin Clinical Trials in Major Depressive Disorder on ClinicalTrials.gov: A Cross-Sectional Analysis
Pharmacopsychiatry – April 17, 2025
Summary
Only four of eleven identified psilocybin clinical trial protocols for major depressive disorder (MDD) and treatment-resistant depression (TRD) adequately addressed regulatory standards. While superficially compliant, these trials, often using 25 mg of the alkaloid, overlooked critical drug interactions and potential biases like expectancy theory. Two protocols were double-blind. For psychiatry and psychology, ensuring rigorous oversight in medicine is crucial for psychedelics, understanding their neurotransmitter receptor influence. Patients with schizoaffective disorder were excluded, highlighting compliance gaps in these drug studies.
Abstract
Abstract Regulatory compliance is crucial in the clinical development of psychedelic substances, including psilocybin. This study aimed to examine ...
Psilocybin's lasting action requires pyramidal cell types and 5-HT2A receptors.
Nature – June 01, 2025
Summary
A single dose of psilocybin can create lasting changes in specific brain cells, offering hope for stress-related mental health treatments. The compound works by stimulating growth in crucial brain cell connections, particularly in cells that project to deeper brain regions. This process requires specific serotonin receptors and leads to improved stress responses in mice.
Abstract
Psilocybin is a serotonergic psychedelic with therapeutic potential for treating mental illnesses1-4. At the cellular level, psychedelics induce st...
Comparing Antidepressant Effects of Psilocybin-Assisted Psychotherapy in Individuals That Were Unmedicated at Initial Screening Versus Individuals Discontinuing Medications for Study Participation: Comparaison des effets antidépresseurs de la psychothérapie assistée par la psilocybine (PAP) chez les personnes non médicamentées à la sélection initiale et les personnes ayant arrêté les médicaments pour participer à l’étude
The Canadian Journal of Psychiatry – March 25, 2025
Summary
Patients experiencing major depressive episodes achieved comparable relief from depression, anxiety, and suicidal ideation, whether they tapered off antidepressants (n=18) or were unmedicated (n=9) when receiving psilocybin-assisted psychotherapy. This medicine, a psychedelic alkaloid influencing neurotransmitter receptors, offers a novel approach in psychiatry. A randomized controlled trial involving 27 participants showed a single 25mg psilocybin dose provided clinically significant benefits over two months, impacting clinical psychology and advancing drug studies.
Abstract
Objective: To compare changes in depression, anxiety, and suicidality symptoms after a single 25 mg oral dose of psilocybin between treatment-resis...
Pyramidal cell types and 5-HT 2A receptors are essential for psilocybin’s lasting drug action
OpenAlex – November 03, 2024
Summary
Silencing specific brain cells can completely eliminate the therapeutic benefits of psilocybin. This hallucinogen, an alkaloid studied in psychedelics and drug studies, increases dendritic spine density in two pyramidal cell types. However, only subcortical-projecting (PT) neurons, when silenced, abolish the drug's action on stress-related behaviors. Psilocybin boosts synaptic activity and firing rates exclusively in PT neurons. This drug's action relies on the 5-HT2A receptor, a key neurotransmitter receptor influencing behavior. This neuroscience and pharmacology insight pinpoints PT cells and the 5-HT2A receptor as crucial for psilocybin's long-term effects.
Abstract
Abstract Psilocybin is a serotonergic psychedelic with therapeutic potential for treating mental illnesses 1–4 . At the cellular level, psychedelic...
Single-dose psilocybin for U.S. military Veterans with severe treatment-resistant depression - A first-in-kind open-label pilot study.
Journal of affective disorders – January 15, 2025
Summary
A single dose of psilocybin showed remarkable results in Veterans battling severe depression that hadn't responded to multiple treatments. In this groundbreaking exploration, 60% of participating Veterans experienced significant relief from depression within three weeks, with over half achieving complete remission. The treatment proved effective even for those with PTSD, offering new hope for Veterans struggling with treatment-resistant depression.
Abstract
The enduring and severe depression often suffered by Veterans causes immense suffering and is associated with high rates of suicide and disability....
The Black Book of Psychotropic Dosing and Monitoring.
Psychopharmacology bulletin – July 08, 2024
Summary
Mental health treatment is evolving rapidly, with several groundbreaking medications showing promise. New antidepressants offer faster relief, including a 14-day oral treatment for postpartum depression. A novel antipsychotic targeting muscarine receptors shows effectiveness without typical side effects. Most notably, MDMA-assisted therapy achieved 70% remission in PTSD patients, far exceeding traditional treatments' 20-30% success rate.
Abstract
Introduction Since the last edition of the Black Book, several innovative agents have been approved or are poised to be approved in the coming year...
Race and ethnicity moderate the associations between lifetime psilocybin use and past year hypertension
Frontiers in Psychiatry – June 24, 2024
Summary
Psilocybin use appears linked to better cardiovascular health, but this benefit isn't universal across all racial and ethnic groups. A large demography study analyzed data from the National Survey on Drug Use and Health (2005–2014), revealing Non-Hispanic White individuals who used psilocybin had 17% reduced odds of past-year hypertension (odds ratio: 0.83). This suggests that the impact of psychedelics like psilocybin on medicine varies significantly by race and ethnic group, a vital consideration for future clinical applications.
Abstract
Background Hypertension is a major source of morbidity and mortality worldwide, particularly for racial and ethnic minorities who face higher rates...
Efficacy of psilocybin for treating symptoms of depression: systematic review and meta-analysis
BMJ – May 01, 2024
Summary
Psilocybin, a hallucinogen, significantly improves depression symptoms, a comprehensive meta-analysis concludes. This systematic review, drawing from extensive digital databases including MEDLINE, synthesized data from 436 participants (228 female) across seven studies. It found a substantial benefit (Hedges’ g=0.66) on depression scores. Greater improvements (g=0.88) were observed for secondary depression and among individuals with prior psychedelic use. This psychiatry and medicine research highlights psilocybin's potential in drug studies, contributing to complementary medicine's understanding of this unique alkaloid.
Abstract
Abstract Objective To determine the efficacy of psilocybin as an antidepressant compared with placebo or non-psychoactive drugs. Design Systematic ...
Valuing the Acute Subjective Experience
Perspectives in biology and medicine – January 01, 2024
Summary
A compelling idea emerges in **psychology**: experiences with **hallucinogens** like **psilocybin** and **MDMA** may hold intrinsic **value** (mathematics) beyond measurable therapeutic outcomes. While **medicine** and **mental health** research often focus on symptom alleviation or well-being increases, this essay challenges that narrow view. It explores how the acute subjective experience, impacting **consciousness**, could be profoundly valuable in itself. Drawing on aesthetics and **epistemology**, it offers **psychotherapists** and **social psychology** a richer understanding of these **psychedelics**, moving beyond solely outcome-based evaluations in **drug studies**.
Abstract
ABSTRACT: Psychedelics, including psilocybin, and other consciousness-altering compounds such as 3,4-methylenedioxymethamphetamine (MDMA), currentl...
Effects of DMT on mental health outcomes in healthy volunteers
Scientific Reports – February 07, 2024
Summary
Intravenous DMT significantly improved mental health, reducing depression within two weeks. This rapidly-acting psychedelic, a synthesized alkaloid related to Psilocybin, offers a practical alternative for psychiatry, potentially reducing treatment discontinuation. In a placebo-controlled group of 13, Neuroticism also decreased. Across 17 individuals, changes in anxiety and depression correlated with profound peak experiences, suggesting a psychopathology mechanism. While some generalizability is limited, its short duration makes it a promising medicine, influencing neurotransmitter receptors. This clinical psychology development could transform mental health.
Abstract
Abstract Psilocybin, a serotonergic psychedelic, is being increasingly researched in clinical studies for the treatment of psychiatric disorders. T...
Potential therapeutic effects of an ayahuasca-inspired N,N-DMT and harmine formulation: a controlled trial in healthy subjects.
Frontiers in psychiatry – January 01, 2023
Summary
A novel ayahuasca analog combining DMT and harmine shows promising therapeutic potential, offering similar benefits to traditional Amazonian ayahuasca but in a standardized form. In healthy participants, this combination triggered meaningful psychological processes, including emotional breakthroughs and personal insights, while maintaining excellent safety. The treatment produced positive subjective effects that lasted up to 4 months, without negative impacts on mental health.
Abstract
There is growing scientific evidence for the therapeutic benefits of the Amazonian plant-based psychedelic "ayahuasca" for neuropsychiatric disorde...
Ayahuasca-induced personal death experiences: prevalence, characteristics, and impact on attitudes toward death, life, and the environment
Frontiers in Psychiatry – December 19, 2023
Summary
Over half of Ayahuasca participants experience a profound "personal death" during ceremonies, a significant psychological phenomenon. Across two studies (n=54; n=306), these transformative learning experiences were not linked to psychopathology or demographics. Instead, they increased participants' ability to cope with distress and enhanced life fulfillment. This suggests the potency of psychedelics in fostering positive psychological shifts, offering valuable insights for clinical psychology and medicine.
Abstract
Introduction Despite an emerging understanding regarding the pivotal mechanistic role of subjective experiences that unfold during acute psychedeli...
The effects of Lysergic Acid Diethylamide (LSD) on the Positive Valence Systems: A Research Domain Criteria (RDoC)-Informed Systematic Review.
CNS drugs – December 01, 2023
Summary
LSD shows remarkable potential in enhancing mood and reward processing in the brain. Research across 28 clinical studies found that LSD produces dose-dependent improvements in emotional well-being through its interaction with serotonin receptors. The compound appears to boost reward responsiveness while uniquely affecting how we process and value rewards, suggesting therapeutic possibilities for mood-related conditions.
Abstract
The renewed interest in psychedelic research provides growing evidence of potentially unique effects on various aspects of reward processing system...
Acute but not long-lasting antidepressant-like effect of psilocybin in differential reinforcement of low-rate 72 schedule in rats
Journal of Psychopharmacology – October 16, 2023
Summary
Psilocybin, an alkaloid hallucinogen, delivered an immediate antidepressant-like effect in rats, a key finding for medicine. Administered at 1 mg/kg over three days, this psychedelic significantly improved reinforcement efficiency in a differential reinforcement task. However, neither psilocybin nor LSD (0.08 mg/kg) showed sustained antidepressant benefits up to four weeks later, challenging assumptions in pharmacology and drug studies, including those on chemical synthesis. This psychology experiment illuminates the complex neurotransmitter receptor influence on behavior.
Abstract
Background: In clinical studies, psychedelics including psilocybin and D-lysergic acid diethylamide (LSD) demonstrate rapid and persistent antidepr...
Manic episode following psilocybin use in a man with bipolar II disorder: a case report
Frontiers in Psychiatry – September 22, 2023
Summary
A 21-year-old with bipolar II disorder developed mania after ingesting psilocybin, a potent hallucinogenic alkaloid. While psychiatry explores psilocybin for clinical depression and substance abuse, this single case highlights significant risks for a vulnerable population. The incident underscores the complex influence of psychedelics on neurotransmitter receptors, particularly for individuals with bipolar disorder prone to manic episodes. Such findings are vital for medicine and clinical psychology, informing future drug studies and understanding substance abuse patterns.
Abstract
There has been an increase in research on the topic of psychedelic substances and their effects as treatment options in neuropsychiatric conditions...
Molecular insights into GPCR mechanisms for drugs of abuse.
The Journal of biological chemistry – September 01, 2023
Summary
Recent breakthroughs reveal how common drugs like opioids and cannabinoids interact with cellular receptors called GPCRs. Scientists mapped the precise structure of these receptors, showing how different drugs of abuse bind to them. This explains why opioids, serotonin-based psychedelics, and cannabinoids affect the brain and body so differently, opening paths for safer treatments.
Abstract
Substance abuse is on the rise, and while many people may use illicit drugs mainly due to their rewarding effects, their societal impact can range ...
On the mushrooming reports of “quiet quitting”: Employees’ lifetime psilocybin use predicts their overtime hours worked
Journal of Psychoactive Drugs – July 31, 2023
Summary
Lifetime psilocybin use significantly reduces overtime, impacting workplace psychology. Data from 217,963 U.S. full-time employees reveal individuals using this hallucinogen work an estimated 44,348,400 fewer overtime hours annually. This demographic economics insight is crucial as decriminalization and legalization of psychedelics advance. As medicine and psychiatry explore psilocybin's potential, and Current Population Survey-type data tracks labor trends, understanding such population effects is vital for drug studies.
Abstract
Despite the recent and sharp rise in psychedelic research, few studies have investigated how classic psychedelic use relates to employees' work-rel...
Sub-acute effects of psilocybin on EEG correlates of neural plasticity in major depression: Relationship to symptoms
Journal of Psychopharmacology – June 30, 2023
Summary
A single psilocybin dose doubled specific brain activity linked to neuroplasticity, measured via Electroencephalography (EEG), in 19 individuals with depression. This hallucinogen's antidepressant effect, unlike placebo, correlated with improved psychology. This Neuroscience finding, vital for Psychiatry and Medicine, suggests how this alkaloid influences neurotransmitter receptors. While distinct from anesthesia, these Psychedelics and Drug Studies highlight chemical synthesis's role in advancing our understanding of behavior.
Abstract
Background: Evidence suggests that serotonergic psychedelics (e.g. psilocybin), have rapid-acting and long-lasting antidepressant effects after a s...
Health Benefits and Positive Acute Effects of Psilocybin Consumption: A Quantitative Textual Analysis of User Self-Reported Data
Journal of Psychoactive Drugs – June 22, 2023
Summary
Profound mystical experiences driven by the hallucinogen psilocybin, including ego-dissolution, offer significant mental health benefits. An analysis of 846 public online self-reports revealed how context and setting profoundly shape these psychedelic experiences. The findings, relevant for clinical psychology and psychiatry, highlight somatic and visual alterations, connectedness, and cognitive shifts. Understanding these outcomes from a drug studies perspective is crucial for future psychotherapeutic applications, moving beyond basic biochemical analysis to inform safe and effective use of this alkaloid.
Abstract
There has been growth in the use of psychedelics by the global population in recent years. In addition to recreational and ritualistic use, recent ...
Cannabis-assisted psychotherapy for complex dissociative posttraumatic stress disorder: A case report
Frontiers in Psychiatry – February 09, 2023
Summary
A young woman with complex dissociative posttraumatic stress disorder achieved a 98.5% reduction in pathological dissociation after ten sessions of cannabis-assisted psychotherapy. This psychotherapist-guided treatment combined cognitive and exposure therapies to address severe depersonalization and derealization, common in dissociative and panic disorders. Improved cognition and psychosocial functioning were sustained for over two years. Offering a promising avenue for clinical psychology and psychiatry, it links cannabis to psychedelics and their Neurotransmitter Receptor Influence on Behavior.
Abstract
Background A dissociative subtype of posttraumatic stress disorder, known as “D-PTSD”, has been included in the Diagnostic and Statistical Manual o...
Changes in music-evoked emotion and ventral striatal functional connectivity after psilocybin therapy for depression
Journal of Psychopharmacology – November 26, 2022
Summary
Psilocybin therapy dramatically enhanced music-evoked pleasure, correlating with reduced anhedonia in 19 patients with treatment-resistant depression. Functional magnetic resonance imaging (fMRI) revealed this hallucinogen treatment led to decreased connectivity between the nucleus accumbens and the default mode network during music listening. Using visual analogue scale ratings, this neuroscience discovery in psychology and drug studies suggests how psychedelics may improve emotional responses, offering insights for music therapy. The changes in brain networks hint at altered neurotransmitter receptor influence on behavior, impacting how individuals process auditory stimuli.
Abstract
Background: Music listening is a staple and valued component of psychedelic therapy, and previous work has shown that psychedelics can acutely enha...
Microdosing psilocybin for chronic pain: a case series
Pain – September 05, 2022
Summary
Three individuals suffering from chronic pain found robust relief using low-dose psilocybin, a naturally occurring alkaloid. This case series highlights how these patients, for whom traditional medicine offered little solace, achieved significant pain reduction and decreased reliance on other drugs. The effects occurred without a psychedelic experience and with minimal side effects. For all three, combining psilocybin with exercise magnified relief, with one patient experiencing increased benefit from repeated dosing. This suggests long-term potential in Complementary and Alternative Medicine Studies for chronic pain management.
Abstract
Abstract Psychedelic serotonergic agonists such as psilocybin have recently been shown to produce sustained benefit in refractory depression, end o...
The Selective Serotonin 5-HT2A Receptor Agonist (S)-3-(2,5-Dimethoxy-4-(trifluoromethyl)phenyl)piperidine (LPH-5) Induces Persistent and Robust Antidepressant-Like Effects in Rodents
ACS Pharmacology & Translational Science – May 29, 2025
Summary
A novel **piperidine** compound, LPH-5, demonstrates potent **antidepressant**-like effects in rats, a breakthrough for **Drug Studies**. Its unique **chemistry**, with a **trifluoromethyl** group, allows precise **chemical synthesis**. This **pharmacology** reveals LPH-5 acts as a selective partial **agonist** at the **serotonin 5-HT2A receptor**, showing pronounced selectivity over other **5-HT receptor** subtypes. This specific **receptor** activation profoundly influences **neurotransmitter receptor influence on behavior**, inducing robust, persistent mood improvements. This work, inspired by **alkaloids** like classical **psychedelics**, highlights new treatment potential.
Abstract
Psychedelics have emerged as a promising treatment for mental health disease, and the therapeutic potential of psilocybin and lysergic acid diethyl...
DARK Classics in Chemical Neuroscience: NBOMes
ACS Chemical Neuroscience – October 28, 2019
Summary
Synthetic psychedelics known as NBOMes, derived from the natural alkaloid mescaline through chemical synthesis, emerged in 2010. While their recreational use led to acute toxicity and deaths, prompting Schedule I classification in 2013, these compounds also offer significant value. In neuroscience, specific NBOMes like [¹¹C]Cimbi-36 are crucial biochemical tools for brain imaging, enabling detailed study of serotonin 2A receptors. This dual nature highlights their impact on both public health and our understanding of brain function in cognitive science and psychology.
Abstract
N-Benzylphenethylamines, commonly known as NBOMes, are synthetic psychedelic compounds derived from the phenethylamine class of psychedelics (2C-X ...
Analysis of Psilocybin-Assisted Therapy in Medicine: A Narrative Review
Cureus – February 05, 2022
Summary
Psilocybin, a classic hallucinogen, is emerging as a powerful medicine in psychiatry. Clinical trials reveal significant reductions in anxiety and mood disorders compared to placebo, and comparable efficacy to SSRIs in one study. This pharmacology, rooted in the unique Neurotransmitter Receptor Influence on Behavior of this chemical (an alkaloid), is revolutionizing addiction treatment. Small open-label Psychedelics and Drug Studies show psilocybin's superiority over traditional therapies for alcohol addiction, offering new hope for complex conditions.
Abstract
Psilocybin-containing mushrooms have been consumed by various cultures in many different parts of the world for thousands of years. Psilocybin, a c...
Psilocybin occasioned mystical‐type experiences
Human Psychopharmacology Clinical and Experimental – June 23, 2020
Summary
Psilocybin-occasioned mystical experiences profoundly correlate with therapeutic benefits for psychiatric conditions. This narrative review in clinical psychology emphasizes the hallucinogen psilocybin's potential as a psychological intervention. Since 2006, medicine and psychiatry have seen significant advancements in psilocybin-assisted psychotherapy. While pharmacological actions, informed by chemical synthesis and alkaloids, are discussed, understanding neuromechanistic processes requires further biochemical analysis and sensing techniques. Future clinical trials integrating a psychotherapist show promise, despite funding and societal resistance impacting Psychedelics and Drug Studies.
Abstract
Abstract Objective Research into psychedelic therapy models has shown promise for the treatment of specific psychiatric conditions. Mystical‐type e...
MDMA/ecstasy use and psilocybin use are associated with lowered odds of psychological distress and suicidal thoughts in a sample of US adults
Journal of Psychopharmacology – January 01, 2022
Summary
Remarkably, in an analysis of 484,732 adults, lifetime MDMA (Ecstasy) use correlated with 10% reduced odds of past year suicidal ideation and planning. Psilocybin, a hallucinogen, showed 22% reduced odds of past month psychological distress and 10% reduced odds of suicidal thinking. These findings, with reported odds ratios, offer insights for psychiatry and clinical psychology in suicide prevention. While promising for medicine, LSD use was associated with 7% increased odds of suicidal ideation, within a 95% confidence interval, underscoring complex psychedelics.
Abstract
Background: Suicide is one of the leading causes of death worldwide and rates within the United States have risen over the past two decades. Hence,...
Altered states: psilocybin for treatment-resistant depression
The Lancet Psychiatry – May 17, 2016
Summary
A pilot in Psychiatry suggests Psilocybin, a powerful hallucinogen, offers hope for Treatment-resistant depression. In a feasibility study with 12 patients, a regimen combining synthesized psilocybin with psychological support reduced depression scores by around 10 points on the Hamilton Depression Scale after one week. This Medicine, documented in medical literature and Psychedelics and Drug Studies, showed promising safety and preliminary efficacy, with about half the participants still experiencing benefits at three months. This offers hope for the 20% of patients with depression unresponsive to conventional treatments.
Abstract
"Alice remained looking thoughtfully at the mushroom for a minute, trying to make out which were the two sides of it; and as it was perfectly round...
Psilocybin use is associated with lowered odds of crime arrests in US adults: A replication and extension
Journal of Psychopharmacology – January 01, 2022
Summary
Psilocybin use is linked to significantly lowered odds of arrest. National demography data from 211,549 individuals showed lifetime psilocybin use associated with reduced odds for 7 of 11 past-year arrest types (odds ratios 0.30-0.73). This offers criminology a new perspective on reducing recidivism within prison populations. Mescaline also reduced odds for drug possession. These psychology and psychedelics and drug studies findings suggest avenues for medicine.
Abstract
Background: The United States boasts the largest prison population in the world, conferring significant direct and indirect costs (e.g. lost wages ...
Psilocybin as a Novel Pharmacotherapy for Treatment-Refractory Anorexia Nervosa
OBM Neurobiology – June 24, 2021
Summary
Anorexia nervosa, a severe psychiatry challenge, sees current psychological intervention remission rates below 50%. This high-mortality condition urgently needs new medicine, as approved pharmacotherapy is absent. Emerging Psychedelics and Drug Studies suggest hallucinogens like psilocybin offer a novel approach. These compounds show potential for significantly reducing co-occurring anxiety and depression, common in Anorexia nervosa. Influencing Neurotransmitter Receptor Influence on Behavior, this could be a vital treatment in psychology for treatment-resistant patients, offering new hope.
Abstract
Anorexia Nervosa (AN) is a major health problem with one of the highest mortalities and treatment costs of any psychiatric condition. Cognitive beh...
Psilocybin for Treating Psychiatric Disorders: Is it a Psychonaut Legend or a Promising Therapeutic Perspective?
Preprints.org – June 28, 2021
Summary
Psilocybin, a potent hallucinogen from over 200 mushroom species, is re-emerging in modern Psychiatry. Identified via chemical synthesis and alkaloids research in 1957, this compound, now central to Psychedelics and Drug Studies, was scheduled in 1970. However, Complementary and Alternative Medicine Studies in Psychology and Medicine now suggest significant therapeutic potential. A psychotherapist's perspective indicates it may effectively address pathological Anxiety, Mood disorders, and Addiction, offering a new outlook. This shift provides a fresh perspective on mental health.
Abstract
Psychedelics extracted by plants have been used in religious, spiritual and mystic practices for millennia. In 1957, Dr. Hofmann have identified an...
Enhanced visual contrast suppression during peak psilocybin effects: A psychophysical study
OpenAlex – January 11, 2024
Summary
Psilocybin profoundly alters visual perception, intensifying a phenomenon called surround suppression. Participants (n=6) reported stronger suppression of a visual stimulus's perceived contrast after 25mg of this hallucinogen compared to placebo. This effect, crucial for understanding visual cortex function in psychology, correlated positively with subjective 'visual hallucinations.' This suggests a neurotransmitter receptor influence on behavior. Given weakened surround suppression in major depressive disorder, these insights into psilocybin's impact on perception offer a compelling avenue for psychedelic therapies.
Abstract
In visual perception, an effect known as surround suppression occurs wherein the apparent contrast of a center stimulus is reduced when it is prese...
Psilocybin causes sex, time, and dose dependent alterations in brain signaling pathways
OpenAlex – December 17, 2024
Summary
Low-dose psilocybin, a potent hallucinogen, exhibits molecular effects in the brain that can outlast high doses, persisting for at least seven days. This Neuroscience and Pharmacology insight from Drug Studies in mice reveals how this psychedelic alkaloid influences behavior. Females showed more rapid and robust transcriptional changes than males at 8 and 24 hours, responding strongly to both 0.25 mg/kg and 1 mg/kg doses. Such findings are crucial for Medicine and Psychology, informing future psilocybin treatment strategies and understanding its Neurotransmitter Receptor Influence on mental health conditions.
Abstract
Abstract Psilocybin is a psychedelic tryptamine that has emerged as a potential candidate for the treatment of a variety of conditions, including t...
Neural mechanisms underlying psilocybin’s therapeutic potential – the need for preclinical in vivo electrophysiology
Journal of Psychopharmacology – May 30, 2022
Summary
Psilocybin, a potent natural hallucinogen, shows immense promise for treating brain disorders. While Neuroscience and Psychology explore its profound effects on consciousness and cognition, the precise neurophysiology remains complex. Neuroimaging reveals its influence on the prefrontal cortex and default mode network, but how this psychedelic compound, an alkaloid, specifically modulates biological neural networks and neurotransmitter receptors is still being elucidated. Electrophysiology is crucial for clarifying these mechanisms, advancing drug studies, and unlocking its therapeutic potential.
Abstract
Psilocybin is a naturally occurring psychedelic compound with profound perception-, emotion- and cognition-altering properties and great potential ...
Ministry of the Mushroom
International Journal for the Study of New Religions – March 23, 2022
Summary
Beyond clinical applications, a compelling trend shows psilocybin mushroom churches emerging, offering unique spiritual pathways. These communities foster "sacred sensemaking," interpreting the hallucinogen psilocybin as a divine sacrament through ritual practices. This sociological shift contrasts with traditional Christian ministry, suggesting a distinct psychological approach to spiritual exploration. It expands psychedelics and drug studies beyond chemical synthesis, hinting at diverse academic research themes, from the aesthetics of ritual to the psychoanalytic depth of personal transformation.
Abstract
Recently there has been a surge of renewed interest in the psychedelic compound psilocybin. In particular, psilocybin is being studied in clinical ...
Psilocybin-Assisted Therapy Found to Improve Depression, Offer Other Benefits
Psychiatric News – May 23, 2022
Summary
Psilocybin therapy offers substantial, lasting relief for major depression. In a group of 24 individuals, this hallucinogen, combined with psychotherapy, led to 75% achieving treatment response and 58% remission after one year, with no serious adverse effects. This advance in Psychiatry and Clinical psychology, impacting Medicine, highlights psychedelics' potential in Mental Health Research Topics, even if personal meaning didn't directly predict depression improvement.
Abstract
Back to table of contents Previous article Next article Clinical & ResearchFull AccessPsilocybin-Assisted Therapy Found to Improve Depression, Offe...
Psilocybin-Assisted Psychotherapy in Palliative Care
Oxford University Press eBooks – December 01, 2022
Summary
Psilocybin-assisted psychotherapy is re-emerging as a powerful psychological intervention for profound end-of-life distress. Despite advances in palliative care medicine, psychiatric and existential anguish persist, often unaddressed. Contemporary research in Psychiatry and Psychology is now examining psilocybin, delivered by a psychotherapist, to alleviate this suffering. Building on earlier Psychedelics and Drug Studies, this approach, encompassing Chemical synthesis and alkaloids and Complementary and Alternative Medicine Studies, offers a potential paradigm shift. It explores safety and efficacy data to transform end-of-life well-being.
Abstract
Abstract Following a decades-long hiatus and building on an innovative research model first developed from the 1960s to 1970s utilizing psychedelic...
Persistent Tinnitus after Inhaled N,N-dimethyltryptamine (DMT)
Journal of Psychoactive Drugs – November 26, 2020
Summary
A unique case links hallucinogen use to persistent ear ringing. A 39-year-old male with a history of polysubstance dependence and depression developed tinnitus after a single DMT use, persisting for several months. The context included weekly LSD microdosing. Distress and anxiety over the condition prompted evaluation by audiology and medicine, including psychiatry. Psilocybin microdoses exacerbated symptoms on two occasions. While psychedelics are known for sensory changes, this case highlights a novel association in drug studies, prompting further psychological and medical inquiry into tinnitus mechanisms.
Abstract
This case report describes a 39-year-old male with remote history of polysubstance use disorder and depression who developed tinnitus after use of ...
Long-Term Analysis of Psilocybin in Cancer Patients With Distress
Oncology Times – March 26, 2020
Summary
A single dose of psilocybin, a compound from psychedelic mushrooms, offered profound, lasting relief for cancer patients facing existential distress. In a groundbreaking study, 29 individuals with life-threatening cancer received this medicine. Follow-up after an average of 3.2 to 4.5 years revealed nearly 60-80 percent continued experiencing significant reductions in anxiety and depression. This suggests a powerful, enduring benefit for mental health, a key area within Complementary and Alternative Medicine Studies, potentially transforming intensive care medicine approaches to patient well-being beyond traditional drug studies.
Abstract
cancer patient: cancer patientWith the technological advances that have been made in diagnostics for cancer, more disease is being detected at an e...
Modulation of Serum Brain-Derived Neurotrophic Factor by a Single Dose of Ayahuasca: Observation From a Randomized Controlled Trial
Frontiers in Psychology – June 04, 2019
Summary
Ayahuasca significantly boosts Brain-derived neurotrophic factor (BDNF) levels, a key neurotrophic factor, suggesting a mechanism for its antidepressant effects. In a randomized controlled trial, 35 individuals receiving Ayahuasca—including patients with treatment-resistant depression and healthy controls—showed higher BDNF levels after 48 hours compared to 34 receiving Placebo. This finding, relevant to Psychology, Internal medicine, and Endocrinology, highlights how serotonergic psychedelics, influencing neurotransmitter receptor behavior, may offer novel antidepressant strategies for depression.
Abstract
Serotonergic psychedelics are emerging as potential antidepressant therapeutic tools, as suggested in a recent randomized controlled trial with aya...